Industry
Biotechnology
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers. The company's lead product candidate is CTM-N2D, which consists of expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, which utilizes iPSC as a starting material to generate gdNKT, a synthetic hybrid of a gamma delta T cell and a NK cell; and CTM-GDT, a product candidate that consists of expanded gamma delta T cells, and exploits the multiple recognition system of gamma delta T cell to recognize and treat a range of cancers. The company was incorporated in 2018 and is headquartered in Singapore.
Loading...
Open
2.93
Mkt cap
31M
Volume
5K
High
3.00
P/E Ratio
-12.93
52-wk high
5.50
Low
2.62
Div yield
N/A
52-wk low
1.20
Portfolio Pulse from Benzinga Newsdesk
October 10, 2024 | 1:19 pm
Portfolio Pulse from Benzinga Newsdesk
October 03, 2024 | 11:34 am
Portfolio Pulse from Benzinga Newsdesk
July 17, 2024 | 12:02 pm
Portfolio Pulse from Benzinga Newsdesk
July 17, 2024 | 11:11 am
Portfolio Pulse from Benzinga Newsdesk
June 11, 2024 | 11:33 am
Portfolio Pulse from Benzinga Newsdesk
March 20, 2024 | 12:46 pm
Portfolio Pulse from Benzinga Newsdesk
March 18, 2024 | 10:16 am
Portfolio Pulse from Benzinga Newsdesk
March 04, 2024 | 10:05 am
Portfolio Pulse from Benzinga Insights
February 14, 2024 | 9:31 pm
Portfolio Pulse from Benzinga Insights
February 09, 2024 | 1:06 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.